Daiichi Sankyo Co., Ltd. has entered into a strategic collaboration with AgonOx, Inc. to develop an undisclosed immuno-oncology target. AgonOx is a privately-held biotechnology company developing novel immunotherapy drugs targeting key regulators of the immune response to cancer.
 
The companies will collaborate on preclinical development of the program, after which Daiichi Sankyo has an exclusive option to research, develop, manufacture and commercialize the program worldwide. Financial terms of the agreement were not disclosed.
 
“We are excited to collaborate with AgonOx, which has extensive expertise in validating the expression and function of immuno-oncology targets,” said Antoine Yver, MD, MSc, executive vice president and Global Head, Oncology R&D, Daiichi Sankyo. “While this collaboration will help strengthen our immuno-oncology capabilities, it also aligns with our overall mission of discovering and delivering science that can change the standard of care for patients with cancer.”